Table 4.
Study | N | Tool | Inputs | Outcomes |
---|---|---|---|---|
(Daemen et al. 2009)[61] | 55 | Genetic integration | DNA, CNV | Cancer outcome |
| ||||
(Kuru et al. 2013)[59] | 50 | Diagnostics | mpMRI | PIRADS |
| ||||
(Zumsteg et al. 2013)[55] | 1024 | Risk stratification | Risk factors, Gleason score, biopsy | Risk group |
| ||||
(Beyan et al. 2014) [62] | Model | Genetic integration | SNPs | Various |
| ||||
(Kent and Vickers 2015)[60] | Model | Diagnostics | Clinical and tumor features | Life expectancy |
| ||||
(Gnanapragasam et al. 2016)[56] | 10139 | Risk stratification | PSA, stage, Gleason score | Risk group |
| ||||
(Epstein et al. 2016)[57] | 26325 | Risk stratification | PSA, stage | Gleason grade |
| ||||
(Gries et al. 2017)[58] | 120 | Utility values | Utility's 18 health states | Utility's 243 heath states |
Abbreviations. N: Number of patients; CNV: copy number variation; SNP: single nucleotide polymorphism; PSA: prostate specific antigen; mpMRI: multiparametric magnetic resonance imaging; PIRADS: Prostate Imaging Reporting and Data system.